Andrew J. Schwab
CIK 1598549 · Co-CEO · last filed 2026-09-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4 EMBARCADERO CENTER, SUITE 3110
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SKYE | Director | 981,269 | $1.57 | $1.54M | -$3.00M | 9 | 2026-09-24 |
| CAMP | Director | 2,033,270 | $3.21 | $6.53M | $7.50M | 8 | 2026-08-31 |
| TRDA | 10%+ Owner | 3,941,623 | $4.75 | $18.72M | -$4.84M | 1 | 2026-08-03 |
| ARTV | 10%+ Owner | 1,182,054 | $6.16 | $7.28M | $60.00M | 1 | 2024-07-24 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 3,888,992 | $14.59 | $56.74M | -$45.00M | 3 | 2024-02-02 |
| Pear Therapeutics, Inc. (PEARW) Delisted | Director | 12,989,936 | $0.01 | $76.6K | -$8.38M | 2 | 2022-09-16 |
| RLYB | 10%+ Owner | 162,760 | $16.65 | $2.71M | -$7.80M | 1 | 2022-05-25 |
| IPI Legacy Liquidation Co (IMPL) Delisted | 10%+ Owner | 1,849,456 | $0.24 | $445.9K | $60.38M | 1 | 2021-04-29 |
| CABA | 10%+ Owner | 380,218 | $1.35 | $513.3K | -$35.22M | 1 | 2021-01-12 |
| 5:01 Acquisition Corp. (FVAM) Delisted | Co-CEO | 365,126 | $10.00 | $3.65M | $0 | 4 | 2020-12-01 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 3,123,303 | $5.67 | $17.71M | $5.00M | 1 | 2020-05-28 |
| ARVN | 10%+ Owner | 3,888,216 | $7.31 | $28.42M | -$106.29M | 2 | 2019-07-01 |
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | 94,489 | $84.95 | $8.03M | -$33.30M | 1 | 2019-06-25 | |
| FIXX | 10%+ Owner | 12,302 | $6.93 | $85.3K | -$82.79M | 2 | 2019-05-20 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | 10%+ Owner | 65,699 | — | — | $10.00M | 1 | 2015-02-06 |
| FLXN | Director | 1,512,076 | $24.16 | $36.53M | $0 | 2 | 2014-03-04 |
Recent Filings · Page 2 of 5
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-09 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2025-09-15 | CAMP | Grant (A) | +2,941,176 | $4.50M | EDGAR |
| 2025-08-22 | SKYE | Sell (S) | −231,405 | -$800.5K | EDGAR |
| 2025-06-27 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2025-02-26 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-10-30 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-10-15 | CAMP | Mixed | +2,927,915 | $10.00M | EDGAR |
| 2024-09-13 | SKYE | Sell (S) | −266,337 | -$1.75M | EDGAR |
| 2024-07-24 | ARTV | Mixed | +14,119,824 | $88.26M | EDGAR |
| 2024-03-15 | — | Grant (A) | +450,000 | $4.50M |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.